Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4-5
pubmed:dateCreated
1993-3-29
pubmed:abstractText
Epstein-Barr virus (EBV) DNA is frequently identified in benign and malignant lymphoproliferative conditions. As shown by in situ hybridization studies viral DNA is localized within malignant cells as well as benign lymphocytes. Clonal and nonclonal EBV genomes are present in Hodgkin's disease (HD), lymphomas of the immunocompromised host and reactive lymph node hyperplasia. Lytic infection with formation of linear genomes is observed in the same conditions but appears to be infrequent in HD as shown by quantitation of mRNA coding for viral capsid antigen. Expression of the oncogene LMP (latent membrane protein) is seen in Sternberg-Reed (SR) cells and immunoblasts of AIDS-related lymphoma and infectious mononucleosis (IM). In HD, the region of the BNLF1 oncogene coding for the amino terminal and transmembrane domains (associated with oncogenic function) of LMP appears to be homogeneous whereas the region coding for the intracytoplasmic (carboxy terminal) domain of LMP is heterogeneous. Cytological similarities between SR cells and immunoblasts of IM and AIDS-related lymphomas are consistent with the hypothesis that the BNLF1 oncogene is one possible inducer of morphological features of SR cells. Whether chromosomal integration of EBV DNA is an important factor in activation of such a transforming activity remains to be elucidated. EBV DNA positive and negative HD cases with numerous SR cells lack significant mRNA expression of the two recombinase activating genes (RAG-1 and RAG-2). Therefore the SR cells appear to be derived from lymphocytes beyond the pre-B-cell or common thymocyte stage which may or may not subsequently become infected by EBV.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1042-8194
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:geneSymbol
BLLF1, BNLF1, BZLF1, bcl-2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
319-25
pubmed:dateRevised
2005-11-17
pubmed:meshHeading
pubmed-meshheading:1337849-Antigens, Viral, pubmed-meshheading:1337849-Chromosomes, Human, pubmed-meshheading:1337849-Clone Cells, pubmed-meshheading:1337849-DNA, Viral, pubmed-meshheading:1337849-Genes, Viral, pubmed-meshheading:1337849-Herpesvirus 4, Human, pubmed-meshheading:1337849-Hodgkin Disease, pubmed-meshheading:1337849-Humans, pubmed-meshheading:1337849-Immunocompromised Host, pubmed-meshheading:1337849-In Situ Hybridization, pubmed-meshheading:1337849-Lymph Nodes, pubmed-meshheading:1337849-Lymphocytes, pubmed-meshheading:1337849-Lymphoma, pubmed-meshheading:1337849-Oncogenes, pubmed-meshheading:1337849-Polymerase Chain Reaction, pubmed-meshheading:1337849-Reed-Sternberg Cells, pubmed-meshheading:1337849-Tumor Virus Infections, pubmed-meshheading:1337849-Viral Matrix Proteins, pubmed-meshheading:1337849-Viral Structural Proteins, pubmed-meshheading:1337849-Virus Replication
pubmed:year
1992
pubmed:articleTitle
Significance of the detection of Epstein-Barr virus DNA in lymph nodes in patients with Hodgkin's disease.
pubmed:affiliation
Division of Haematology, CHUV University Hospital, Lausanne, Switzerland.
pubmed:publicationType
Journal Article, Review